Bridgeway Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Bridgeway Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Hold	36,500	–	–	﹤0.01%	1018
2026 Q1	$282K	Buy	+36,500	New	+$266K	0.01%	948
2024 Q2	–	Sell	-35,360	Closed	-$1.19M	–	1274
2024 Q1	$1.19M	Buy	+35,360	New	+$1.25M	0.02%	695
2020 Q2	–	Sell	-41,900	Closed	-$569K	–	1301
2020 Q1	$569K	Hold	41,900	–	–	0.01%	725
2019 Q4	$455K	Buy	41,900 +1,900	+5%	+$19.9K	0.01%	1026
2019 Q3	$411K	Buy	+40,000	New	+$432K	0.01%	1021

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bridgeway Capital Management's ARCT Position: Q2 2026 in Review

Bridgeway Capital Management held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 36,500 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

Bridgeway Capital Management first reported a position in ARCT in Q3 2019 and has held it in 6 quarters since. The position peaked at $1.19M in Q1 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Bridgeway Capital Management held 36,500 shares of Arcturus Therapeutics worth $245K as of Q2 2026.
Bridgeway Capital Management left its Arcturus Therapeutics share count unchanged in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1018 holding.
Bridgeway Capital Management first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 6 quarters since.
Bridgeway Capital Management's Arcturus Therapeutics position peaked at $1.19M in Q1 2024.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.